(Report ID: 48065) Many drug interactions and side effects can not be detected until the drugs have been used by millions of people, and for a long time. Large, long-term drug safety studies are ideal to discover these real-world drug outcomes. For the first time, eHealthMe enables health professionals and patients to conduct these studies for their drugs. Click here to check your drugs now, in a whole new way. As of Nov, 21, 2008, eHealthMe analyzes 10,180,651 drug interactions and side effects of 21,667 FDA-approved drugs from 1977 to the present. Results on Nov, 21, 2008: 1,011 relevant incidents
Note:
- The incidents can not include all actual occurrences
- Data of 2008 is not complete
DISCLAIMER: All adverse drug reaction material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. Basic information:
| Report ID | Date of submission | Patient age | Patient gender |
| 48065 | Feb, 17, 2006 | 35 | Female |
List of drugs the patient takes:
| Name |
Amnesia |
Bipolar Disorder |
Blood Cholesterol Increased |
Cerebrovascular Accident |
Chondropathy |
Disturbance In Attention |
Gallbladder Disorder |
Gastrooesophageal Reflux Disease |
Hypertension |
Insomnia |
Pancreatitis |
Post-traumatic Stress Disorder |
Syncope |
Transient Ischaemic Attack |
Vulval Cancer |
Results from eHealthMe: 1,011 relevent incidents1) Comparison with the patient's adverse outcomes:
| Name | Count (% of total reports) |
Amnesia | 41 (4.06%) |
Bipolar Disorder | 13 (1.29%) |
Blood Cholesterol Increased | 69 (6.82%) |
Cerebrovascular Accident | 210 (20.77%) |
Chondropathy | 1 (0.10%) |
Disturbance In Attention | 15 (1.48%) |
Gallbladder Disorder | 19 (1.88%) |
Gastrooesophageal Reflux Disease | 91 (9.00%) |
Hypertension | 158 (15.63%) |
Insomnia | 94 (9.30%) |
Pancreatitis | 9 (0.89%) |
Post-traumatic Stress Disorder | 11 (1.09%) |
Syncope | 45 (4.45%) |
Transient Ischaemic Attack | 86 (8.51%) |
Vulval Cancer | 1 (0.10%) |
Death: 0
Cancer: 0
| Name | Count (% of total reports) |
1 | Amnesia | 6 (66.67%) |
2 | Pain | 6 (66.67%) |
3 | Myositis | 5 (55.56%) |
4 | Night Sweats | 5 (55.56%) |
5 | Osteoarthritis | 5 (55.56%) |
6 | Otorrhoea | 5 (55.56%) |
7 | Pain In Extremity | 5 (55.56%) |
8 | Musculoskeletal Disorder | 5 (55.56%) |
9 | Muscle Spasms | 5 (55.56%) |
10 | Inflammation | 5 (55.56%) |
3) Top co-used drugs drugs reported for the past 12 months:
| Name | Count |
1 | Celexa | 7 |
2 | Neurontin | 6 |
3 | Trazodone Hcl | 6 |
4 | Prednisone | 6 |
5 | Cephalexin | 5 |
6 | Cyclobenzaprine Hcl | 5 |
7 | Norflex | 5 |
8 | Folic Acid | 5 |
9 | Dalmane | 5 |
10 | Zoloft | 5 |
Death: 25 (2.47% of total reports)
Cancer: 23 (2.27% of total reports)
| Name | Count (% of total reports) |
1 | Depression | 242 (23.94%) |
2 | Cerebrovascular Accident | 210 (20.77%) |
3 | Myocardial Infarction | 201 (19.88%) |
4 | Chest Pain | 197 (19.49%) |
5 | Anxiety | 162 (16.02%) |
6 | Hypertension | 158 (15.63%) |
7 | Headache | 153 (15.13%) |
8 | Fatigue | 150 (14.84%) |
9 | Dyspnoea | 140 (13.85%) |
10 | Nausea | 138 (13.65%) |
| Name | Count |
1 | Prevacid | 181 |
2 | Neurontin | 167 |
3 | Oxycontin | 142 |
4 | Premarin | 136 |
5 | Ambien | 125 |
6 | Lipitor | 121 |
7 | Celebrex | 113 |
8 | Vicodin | 101 |
9 | Prilosec | 100 |
10 | Xanax | 97 |
Want to have a risk analysis report like this for your drugs? Click here. ADVERTISEMENT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Recent drug risk analysis reports:
|
|
|
 |
|
How to use the report?
Bring a copy of this report to a doctor's appointment to ensure drug risks are fully discussed and understood, in the process of risk and benefit assessment.
|
 |
|
ADVERTISEMENT
|
|
